Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ma Si-Cong¹²,Tang Xin-Ran¹,Long Li-Li¹,Bai Xue¹,Zhou Jian-Guo³,Duan Zhi-Jiao²,Wang Jian¹,Fu Qiang John⁴,Zhu Hong-Bo²,Guo Xue-Jun¹,Zhang Yan-Pei¹²,Guo Ze-Qin¹,Wu De-Hua¹,Dong Zhong-Yi¹^ORCID

Affiliation:

1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

2. Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China

3. Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany

4. Department of Community Health, Tufts University, Medford, USA

Funder

National Natural Science Foundation for Young Scientists of China

Natural Science Foundation of Guangdong Province

Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1909296

Reference39 articles.

1. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

3. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

5. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhalable metal–organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy;Acta Pharmaceutica Sinica B;2024-05

2. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review);International Journal of Oncology;2024-02-13

3. Comparison of survival outcomes between clinical trial participants and non-participants of patients with advanced non-small cell lung cancer: A retrospective cohort study;Heliyon;2023-12

4. Determining the prognosis of Lung cancer from mutated genes using a deep learning survival model: a large multi-center study;Cancer Cell International;2023-11-04

5. The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis;Frontiers in Immunology;2022-11-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3